Corvus Pharmaceuticals, Inc.

NasdaqGM:CRVS 株式レポート

時価総額:US$120.7m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Corvus Pharmaceuticals マネジメント

マネジメント 基準チェック /24

Corvus Pharmaceuticals'の CEO はRick Millerで、 Feb2014年に任命され、 の在任期間は 10.33年です。 の年間総報酬は$ 1.32Mで、 8.3%給与と91.7%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の2.82%を直接所有しており、その価値は$ 3.41M 。経営陣と取締役会の平均在任期間はそれぞれ4.5年と9年です。

主要情報

Rick Miller

最高経営責任者

US$1.3m

報酬総額

CEO給与比率8.3%
CEO在任期間10.3yrs
CEOの所有権2.8%
経営陣の平均在職期間4.5yrs
取締役会の平均在任期間9yrs

経営陣の近況

Recent updates

Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely?

Mar 06
Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely?

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Oct 23
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?

May 16
Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Dec 05
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China

Sep 26

We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate

Aug 14
We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate

Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth

Apr 05
Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth

We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely

Dec 15
We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely

Checking In On Corvus Pharmaceuticals

Dec 10

Corvus: Surging On AstraZeneca CD73 Success With Key Data Readout Looming

Sep 22

We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth

Aug 26
We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth

Corvus Pharmaceuticals initiated buy at Cantor with a Street-high target

May 27

Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?

May 08
Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?

The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares

Feb 19
The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Feb 07
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like

Dec 16
Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like

Corvus Pharmaceuticals EPS misses by $0.06

Oct 29

CEO報酬分析

Corvus Pharmaceuticals の収益と比較して、Rick Miller の報酬はどのように変化したか?
日付総報酬給与会社業績
Mar 31 2024n/an/a

-US$25m

Dec 31 2023US$1mUS$110k

-US$27m

Sep 30 2023n/an/a

-US$30m

Jun 30 2023n/an/a

-US$39m

Mar 31 2023n/an/a

-US$41m

Dec 31 2022US$524kUS$300k

-US$41m

Sep 30 2022n/an/a

-US$41m

Jun 30 2022n/an/a

-US$37m

Mar 31 2022n/an/a

-US$40m

Dec 31 2021US$905kUS$300k

-US$43m

Sep 30 2021n/an/a

-US$7m

Jun 30 2021n/an/a

-US$6m

Mar 31 2021n/an/a

-US$5m

Dec 31 2020US$1mUS$300k

-US$6m

Sep 30 2020n/an/a

-US$44m

Jun 30 2020n/an/a

-US$46m

Mar 31 2020n/an/a

-US$48m

Dec 31 2019US$1mUS$300k

-US$47m

Sep 30 2019n/an/a

-US$46m

Jun 30 2019n/an/a

-US$46m

Mar 31 2019n/an/a

-US$44m

Dec 31 2018US$1mUS$300k

-US$47m

Sep 30 2018n/an/a

-US$48m

Jun 30 2018n/an/a

-US$51m

Mar 31 2018n/an/a

-US$54m

Dec 31 2017US$1mUS$302k

-US$56m

報酬と市場: Rickの 総報酬 ($USD 1.32M ) は、 US市場 ($USD 673.68K ) の同規模の企業の平均を上回っています。

報酬と収益: Rickの報酬は増加しましたが、会社は利益を上げていません。


CEO(最高経営責任者

Rick Miller (73 yo)

10.3yrs

在職期間

US$1,321,351

報酬

Dr. Richard A. Miller, also known as Rick, M.D., serves as Director of BrainScope Company Inc. since September 2023. He is a Co-Founder of Corvus Pharmaceuticals, Inc. and has been its Chief Executive Offi...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Richard Miller
Co-Founder10.3yrsUS$1.32m2.82%
$ 3.4m
Peter Thompson
Co-Founder & Independent Directorno dataUS$95.35k0%
$ 0
Leiv Lea
Chief Financial Officer9.6yrsUS$660.76k0.45%
$ 545.1k
William Jones
Senior Vice President of Pharmaceutical Development4.5yrsUS$616.26k0.25%
$ 296.8k
James Rosenbaum
Senior Vice President of Research1.9yrsデータなしデータなし
Jeffrey Arcara
Chief Business Officerless than a yearデータなしデータなし

4.5yrs

平均在職期間

67yo

平均年齢

経験豊富な経営陣: CRVSの経営陣は 経験豊富 であると考えられます ( 4.5年の平均在職年数)。


取締役

名称ポジション在職期間報酬所有権
Richard Miller
Co-Founder10.4yrsUS$1.32m2.82%
$ 3.4m
Peter Thompson
Co-Founder & Independent Director9.6yrsUS$95.35k0%
$ 0
Elisha Gould
Independent Director9.6yrsUS$101.35k0%
$ 0
Linda Grais
Independent Director5.4yrsUS$97.35k0.016%
$ 19.3k
Ian T. Clark
Independent Director7.4yrsUS$93.35k0%
$ 0
Scott William Morrison
Independent Director8.5yrsUS$109.35k0%
$ 0

9.0yrs

平均在職期間

66.5yo

平均年齢

経験豊富なボード: CRVSの 取締役会経験豊富 であると考えられます ( 9年の平均在任期間)。